DelveInsight’s latest 7MM report, “Relapsed/Refractory Multiple Myeloma Market Report” offers a comprehensive analysis of market dynamics, epidemiology trends, and emerging therapies. The report provides detailed forecasts and insights into the current and future treatment landscape across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, helping stakeholders navigate the evolving market.
Some of the key facts of the Relapsed/Refractory Multiple Myeloma Market Report:
• The total relapsed/refractory multiple myeloma market size is estimated to grow with a significant CAGR during the study period (2019-2032).
• Globally, over 138K new cases of multiple myeloma are diagnosed each year, with most patients eventually experiencing relapse or becoming refractory to treatment.
• In 2023, the 7MM reported approximately 75K new multiple myeloma cases, with numbers expected to rise over the forecast period.
• Despite advancements in therapy, attrition rates increase with each subsequent line of treatment: 26% after the second line, escalating to 50% beyond the fifth line.
• The 3-year overall survival rates are approximately 21% for refractory patients and 28% for those with relapsed disease.
• In May 2025, IGI, a clinical-stage biotech company specializing in multispecifics™ for oncology, announced that the FDA granted Fast Track designation for ISB 2001. This designation is for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have failed at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.
• In February 2025, the FDA granted orphan drug designation (ODD) to OPN-6602, an oral small molecule inhibitor of the E1A binding protein (EP300) and CREB-binding protein (CBP), for the treatment of patients with relapsed or refractory multiple myeloma.
• In April 2024, Bristol Myers Squibb and 2seventy bio, Inc. announced that the FDA approved ABECMA® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma. This approval follows the results from the KarMMa-3 trial and applies to patients who have undergone two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
• In March 2024, Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommended CARVYKTI for the treatment of adult patients with Relapsed/Refractory Multiple Myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an IMiD and who are refractory to lenalidomide
• Leading Relapsed/Refractory Multiple Myeloma therapies include Mezigdomide, felzartamab, Elranatamab, CART-ddBCMA, Magrolimab, PHE885, Encorafenib, Human BCMA Targeted T Cells Injection, Marizomib, Iopofosine, Modakafusp Alfa, STI-6129, HDP 101, ISB 1442, ALLO-605, TAK-981, HPN217, LAVA-051, EMB-06, REGN5459, BGB-11417, Descartes-25, CID-103, FT576, KTX-1001, OriCAR-017, ANV419, LMY-920, SEA-BCMA, TTI-622, and others.
• Leading companies in the Relapsed/Refractory Multiple Myeloma market include Bristol-Myers Squibb, Allogene Therapeutics, Karyopharm Therapeutics, Gracell Biopharmaceuticals, Genentech, Cartesian Therapeutics, Arcellx, Pfizer, Gadeta, Celyad Oncology, Ionis Pharmaceuticals, Ichnos Sciences, AbbVie, Caribou Biosciences, ORIC Pharmaceuticals, Juno Therapeutics, Molecular Templates, Regeneron Pharmaceuticals, Amgen, BeiGene, Epizyme, and others.
To know in detail about the relapsed/refractory multiple myeloma market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Relapsed/Refractory Multiple Myeloma Market Forecast
Relapsed/Refractory Multiple Myeloma Overview
Relapsed/Refractory Multiple Myeloma (RRMM) refers to cases where the cancer returns after initial treatment (relapsed) or does not respond to therapy (refractory). Multiple myeloma is a malignant plasma cell disorder marked by the abnormal proliferation of plasma cells in the bone marrow, leading to bone damage, anemia, kidney dysfunction, and immune suppression. In RRMM, treatment becomes more complex due to acquired drug resistance and disease progression.
Patients with RRMM often undergo multiple lines of therapy, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and more recently, CAR-T cell therapies and bispecific antibodies. Despite these advancements, RRMM remains an area of high unmet need, prompting continued research into innovative therapeutic strategies to extend survival and improve quality of life.
Get a free sample for the relapsed/refractory multiple myeloma market report:https://www.delveinsight.com/report-store/relapsed-refractory-multiple-myeloma-market
Relapsed/Refractory Multiple Myeloma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Relapsed/Refractory Multiple Myeloma Epidemiology Segmentation:
The relapsed/refractory multiple myeloma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total Incident Cases of Multiple Myeloma in the 7MM
• Relapsed/Refractory Mutation Cases of Multiple Myeloma in the 7MM
• FLT3+ Mutation Cases of Multiple Myeloma in the 7MM
• Treated Cases of Multiple Myeloma by line of therapy in the 7MM
Download the report to understand which factors are driving relapsed/refractory multiple myeloma epidemiology trends at Relapsed/Refractory Multiple Myeloma Epidemiology Forecast
Relapsed/Refractory Multiple Myeloma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the relapsed/refractory multiple myeloma market or expected to be launched during the study period. The analysis covers the relapsed/refractory multiple myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the relapsed/refractory multiple myeloma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.
Relapsed/Refractory Multiple Myeloma Market Strengths
• A strong pipeline with novel therapies like bispecific antibodies, CAR-T cells, and targeted agents is driving innovation and expanding treatment options.
• Accelerated approvals and designations such as Fast Track and Breakthrough Therapy by the FDA are expediting the development and availability of new treatments.
Relapsed/Refractory Multiple Myeloma Market Weaknesses
• Advanced therapies, particularly cell and gene therapies, are often prohibitively expensive, limiting patient access and straining healthcare budgets.
• Many patients eventually develop resistance to existing treatments, reducing long-term efficacy and necessitating frequent therapy changes.
Scope of the Relapsed/Refractory Multiple Myeloma Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Relapsed/Refractory Multiple Myeloma Companies: Bristol-Myers Squibb, Allogene Therapeutics, Karyopharm Therapeutics, Gracell Biopharmaceuticals, Genentech, Cartesian Therapeutics, Arcellx, Pfizer, Gadeta, Celyad Oncology, Ionis Pharmaceuticals, Ichnos Sciences, AbbVie, Caribou Biosciences, ORIC Pharmaceuticals, Juno Therapeutics, Molecular Templates, Regeneron Pharmaceuticals, Amgen, BeiGene, Epizyme, and others.
• Key Relapsed/Refractory Multiple Myeloma drugs: Mezigdomide, felzartamab, Elranatamab, CART-ddBCMA, Magrolimab, PHE885, Encorafenib, Human BCMA Targeted T Cells Injection, Marizomib, Iopofosine, Modakafusp Alfa, STI-6129, HDP 101, ISB 1442, ALLO-605, TAK-981, HPN217, LAVA-051, EMB-06, REGN5459, BGB-11417, Descartes-25, CID-103, FT576, KTX-1001, OriCAR-017, ANV419, LMY-920, SEA-BCMA, TTI-622, and others.
• Relapsed/Refractory Multiple Myeloma Therapeutic Assessment: Relapsed/Refractory Multiple Myeloma currently marketed, and Relapsed/Refractory Multiple Myeloma emerging therapies
• Relapsed/Refractory Multiple Myeloma Market Dynamics: Relapsed/Refractory Multiple Myeloma market drivers and Relapsed/Refractory Multiple Myeloma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Relapsed/Refractory Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Relapsed/Refractory Multiple Myeloma Market Access and Reimbursement
To learn more about the key players and advancements in the relapsed/refractory multiple myeloma treatment landscape, visit the Relapsed/Refractory Multiple Myeloma Market Analysis Report
Table of Contents
1. Relapsed/Refractory Multiple Myeloma Market Report Introduction
2. Executive Summary for Relapsed/Refractory Multiple Myeloma
3. SWOT analysis of Relapsed/Refractory Multiple Myeloma
4. Relapsed/Refractory Multiple Myeloma Patient Share (%) Overview at a Glance
5. Relapsed/Refractory Multiple Myeloma Market Overview at a Glance
6. Relapsed/Refractory Multiple Myeloma Disease Background and Overview
7. Relapsed/Refractory Multiple Myeloma Epidemiology and Patient Population
8. Country-Specific Patient Population of Relapsed/Refractory Multiple Myeloma
9. Relapsed/Refractory Multiple Myeloma Current Treatment and Medical Practices
10. Relapsed/Refractory Multiple Myeloma Unmet Needs
11. Relapsed/Refractory Multiple Myeloma Emerging Therapies
12. Relapsed/Refractory Multiple Myeloma Market Outlook
13. Country-Wise Relapsed/Refractory Multiple Myeloma Market Analysis (2019–2032)
14. Relapsed/Refractory Multiple Myeloma Market Access and Reimbursement of Therapies
15. Relapsed/Refractory Multiple Myeloma Market Drivers
16. Relapsed/Refractory Multiple Myeloma Market Barriers
17. Relapsed/Refractory Multiple Myeloma Appendix
18. Relapsed/Refractory Multiple Myeloma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
